CervoMed, a biotech company focused on treatments for age-related brain disorders, announced its participation in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15, 2026. The company will hold a fireside chat and investor meetings to discuss its lead drug candidate, neflamapimod, which targets neuroinflammation and neurodegeneration. CervoMed recently completed Phase 2b trials for dementia with Lewy bodies (DLB) and is planning a Phase 3 trial pending partnership or financing. Additional trials for other brain disorders are ongoing, with new data expected later in 2026.
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
